NovoCure Ltd (NVCR) has provided an announcement.
NovoCure Limited announced that its phase 3 METIS clinical trial for treating brain metastases from non-small cell lung cancer with Tumor Treating Fields therapy has met its primary goal—improving the time to intracranial progression. While preliminary analyses of key secondary outcomes, such as neurocognitive failure and overall survival, didn’t show statistical significance, there were positive trends, particularly in quality of life and time to distant progression. The company plans to submit the data to regulatory authorities, publish in a scientific journal, and present at a scientific congress.
For detailed information about NVCR stock, go to TipRanks’ Stock Analysis page.
